**Review Article**

**Epidemiology of Carbapenemase-Producing Enterobacteriaceae and Acinetobacter baumannii in Mediterranean Countries**

Nassima Djahmi,1,2 Catherine Dunyach-Remy,1,3 Alix Pantel,1,3 Mazouz Dekhil,2 Albert Sotto,1,4 and Jean-Philippe Lavigne1,3

1 National Institute of Health and Medical Research, U1047, Faculty of Medicine, Montpellier 1 University, 30908 Nîmes Cedex 02, France
2 Department of Microbiology, University Hospital Ibn Rochd, 23000 Annaba, Algeria
3 Department of Microbiology, University Hospital Caremeau, 30029 Nîmes Cedex 9, France
4 Department of Infectious Diseases, University Hospital Caremeau, 30029 Nîmes Cedex 9, France

Correspondence should be addressed to Jean-Philippe Lavigne; jean.philippe.lavigne@chu-nimes.fr

Received 8 December 2013; Accepted 22 April 2014; Published 13 May 2014

Academic Editor: Selma Uzunović

Copyright © 2014 Nassima Djahmi et al. This is an open access article distributed under the Creative Commons Attribution License, which permits unrestricted use, distribution, and reproduction in any medium, provided the original work is properly cited.

The emergence and global spread of carbapenemase-producing Enterobacteriaceae and Acinetobacter baumannii are of great concern to health services worldwide. These β-lactamases hydrolyse almost all β-lactams, are plasmid-encoded, and are easily transferable among bacterial species. They are mostly of the KPC, VIM, IMP, NDM, and OXA-48 types. Their current extensive spread worldwide in Enterobacteriaceae is an important source of concern. Infections caused by these bacteria have limited treatment options and have been associated with high mortality rates. Carbapenemase producers are mainly identified among Klebsiella pneumoniae, Escherichia coli, and A. baumannii and still mostly in hospital settings and rarely in the community. The Mediterranean region is of interest due to a great diversity and population mixing. The prevalence of carbapenemases is particularly high, with this area constituting one of the most important reservoirs. The types of carbapenemase vary among countries, partially depending on the population exchange relationship between the regions and the possible reservoirs of each carbapenemase. This review described the epidemiology of carbapenemases produced by enterobacteria and A. baumannii in this part of the world highlighting the worrisome situation and the need to screen and detect these enzymes to prevent and control their dissemination.

**1. Introduction**

Carbapenems are β-lactam group of drugs that are often used as antibiotics of last resort for treating infection due to multidrug-resistant Gram-negative bacilli. They are also stable even in response to extended-spectrum (ESBL) and AmpC β-lactamases. However, this scenario has changed with the emergence in the last few years of carbapenem resistant bacteria both in nonfermenters (Acinetobacter baumannii and Pseudomonas aeruginosa) and in fermenters (Enterobacteriaceae) Gram-negative bacilli [1].

Resistance to carbapenems is mediated by two main mechanisms: (i) production of a β-lactamase (derepressed cephalosporinase or ESBL) with nonsignificant carbapenemase activity combined with decreased permeability due to porin loss or alteration; (ii) production of a carbapenem-hydrolyzing β-lactamase [2].

Carbapenemases have now become a major concern worldwide [3, 4]. They are an increasing concern for global healthcare due to their association with resistance to β-lactam antibiotics and to other classes of antibiotics such as aminoglycosides, fluoroquinolones, and cotrimoxazole [5]. Thus they reduce the possibility of treating infections due to multidrug-resistant strains [6]. The first description of carbapenemase-producing enterobacteria (NmcA) was in 1993 [7]. Since then, large varieties of carbapenemases have been identified belonging to three molecular classes: the Ambler class A, B, and D β-lactamases [8]. They have
emerged and diffused in different parts of the world, including Mediterranean countries, in recent years [2–6, 9]. These enzymes are carried either on chromosome or acquired via plasmids [10].

The aim of this review is to describe the epidemiology of the main carbapenemases circulating in the Mediterranean countries, a region of the world with a great diversity and population mixing. This region includes 11 European countries (Albania, Bosnia, and Herzegovina, Croatia, Spain, France, Greece, Italy, Malta, Montenegro, Monaco and Slovenia), 5 Asian countries (Cyprus, Israel, Lebanon, Syria, Turkey) and 5 African countries (Algeria, Egypt, Libya, Morocco, Tunisia).

2. Class A Carbapenemases

2.1. Enterobacteriaceae. A variety of Class A carbapenemases have been described: some are chromosome encoded (NmcA, Sme, IMI-1, SFC-1) and others are plasmid encoded (KPC, IMI-2, GES derivatives such as GES-1, GES-2, GES-4, and GES-5) but all effectively hydrolyze carbapenems and are partially inhibited by clavulanic acid [8].

KPCs (acronym for K. pneumoniae carbapenemase) are the most frequently encountered enzymes in this group [2]. Since the first report of this enzyme in 1996 isolated from a clinical Klebsiella pneumonia strain in North Carolina, USA [11], the KPC producers had spread around the world and are becoming a major clinical and public health concern [12].

Several KPC clones are disseminating harboring different multilocus sequence type, β-lactamase content, and plasmids. However the bla\textsubscript{KPC} genes are flanked by the same transposon Tn4401 located on conjugative plasmids and are horizontally transferred [13]. This gives to this enzyme an extraordinary spreading capacity [14]. They have been detected more often in Klebsiella spp. [2] but have also been reported in other Enterobacteriaceae [15]. Thirteen variants of KPC are known so far; KPC-2 and KPC-3 are the most frequent worldwide variants [16]. The mortality rate due to infection with a KPC producer ranged from 25% to 69% [2, 17].

The first outbreak of KPC-producing K. pneumoniae outside the United States was described in Israel in 2006 [18]. This strain belonged to the pandemic clone ST258, suggesting an importation from the USA [19]. Moreover, a large range of enterobacteria producing these variants was described in Israel [20–26]. Since then, many studies have reported outbreaks of KPC producers in enterobacterial isolates in Mediterranean countries (Figure 1), in which most cases have been reported so far in Greece, where the situation can be described as endemic [27, 28]. Moreover a recent study showed a wide dissemination of KPC-producing strains to many healthcare institutions in Italy [2, 29]. KPC producers became the most prevalent carbapenemase found in this country [30]. Spain and France have recently described a rapid increase of cases [31, 32]. Single or sporadic hospital outbreaks caused by KPCs isolated from various species were reported [32–34]. KPC-2 is clearly the most prevalent variant in Europe [12, 35]. In most of the cases reported from France, the patients had been transferred from a country where KPC enzymes are endemic (e.g., Israel, Greece, USA, or Italy) [34]. Croatia is another Mediterranean country affected [36].

To date, there is no description of Class A carbapenemases from North African countries. However, KPC producers have already been isolated in an E. coli strain in Algeria (N. Djahmi et al., unpublished data).

2.2. Acinetobacter baumannii. Among the class A carbapenemases, KPCs and GES-type have been described in A. baumannii [37]. KPC-2, KPC-3, KPC-4, and KPC-10 variants were identified in 10 A. baumannii clinical isolates collected in 2009 from 17 hospitals in Puerto Rico [38].

In Mediterranean countries, only GES-type carbapenemase was reported. A GES-14-producing A. baumannii clinical strain was isolated in France. This strain was demonstrated to confer resistance to all β-lactams, including carbapenems [39]. Very recently, an emergence of GES-11 was reported from Turkey [40]. Some strains coexposed both OXA-23 and GES-11. They belonged to ST2, being part of the worldwide distributed clone II group.

3. Class B Carbapenemases

3.1. Enterobacteriaceae. Class B metallo-β-lactamases (MBLs) are mostly of the Verona integron-encoded metallo-β-lactamase (VIM) and IMP types and, more recently, of the New Delhi metallo-β-lactamases-1 (NDM-1) type [8, 41]. MBLs can hydrolyze all β-lactams except monobactams (e.g., aztreonam) [41]. Their activity is inhibited by EDTA but not by clavulanic acid [41].

IMP-1 was the first MBL reported in Serratia marcescens from Japan in 1991 [42]. Since then, MBLs have been observed worldwide [8, 41]. The most commonly found class B carbapenemases are of the VIM type [43], which has been identified in all continents [44]. The death rates associated with MBL producers are high (18% to 67%) [2, 45].

Italy was the first Mediterranean country to report acquired metallo-β-lactamases, with sporadic isolates of VIM-4-producing K. pneumoniae and Enterobacter cloacae [8, 46]. Since then, single or sporadic hospital outbreaks caused by VIM-1 like enzymes were described from various regions in this country [47, 48]. However, such VIM-producing Enterobacteriaceae have not undergone wide dissemination, unlike that observed in Greece during the same period [49]. Endemicity of VIM- and IMP-producing Klebsiella pneumoniae strains has now been noted in Greece [8, 41]. Additionally, outbreaks and single reports of VIM- or IMP-type producers have been reported in several countries of Mediterranean area, such as France [50, 51], Spain [33], Morocco [52], Egypt [53, 54], Algeria [55], and Tunisia [56].

Most recently reported, NDM-1 enzyme is spreading rapidly worldwide [44] notably Central and South America that represented the last zone without description of this enzyme [57, 58]. NDM-1 was initially identified in E. coli and K. pneumoniae in a patient returning to Sweden from India in 2008 [59]. Most of the outbreaks indicated a link with the Indian subcontinent, in some cases with the Balkan countries [60], and the Middle East [61]. Five minor variants
of NDM-1 (NDM-2 to NDM-6) have been now identified in enterobacteria and very recently, a novel variant NDM-7 was detected in *E. coli* in France [62]. Contrarily to other carbapenemase genes, *bla*<sub>NDM-1</sub> is not associated with a single clone. Thus NDM-1 has been identified mostly in nonclonally related *E. coli* and *K. pneumoniae* and to a lesser extent in other enterobacterial species [63]. These enzymes are encoded on highly transmissible plasmids that spread rapidly between bacteria, rather than relying on clonal proliferation. The strains harboring NDM are broadly resistant to many other drug classes in addition to β-lactams and carry a diversity of other resistance mechanisms, which leaves few treatment options (tigecycline or colistin) [63, 64]. NDM-1 producers have been reported in the environment and in the community [2, 63]. They have been identified in Enterobacteriaceae species around the world [59] highlighting the ability of this gene to disseminate in bacteria [65]. Moreover NDM-1 has been identified in *E. coli* ST131, a well-known source of community infections [66, 67].

Single or sporadic hospital outbreaks caused by NDM-1 producing enterobacterial strains were reported from many countries in Mediterranean area (Figure 2): France [68, 69], Italy [70], Lebanon [71], Morocco [52, 72], Spain [33, 73–75], Tunisia [76], and Turkey [77, 78]. Very recently, NDM-5 was identified in *E. coli* in Algeria (Sassi et al., unpublished data). There are no published data yet from Libya, but a very recent study has reported identification of NDM-1 in *K. pneumoniae* from patient transferred from Libya to Tunisia [76], indicating the emergence of this enzyme resistance in Mediterranean countries. Finally an emergence of NDM-producing *K. pneumoniae* was recently reported in Greece [79].

3.2. *Acinetobacter baumannii*. To date, four groups of MBLs have been identified in *A. baumannii*: IMP-like, VIM-like, SIM-like, and recently the NDMs [80].

The first MBL identified in *A. baumannii* strains was IPM-2 reported in 2000 from Italy [81]. Since then, IMP-like, VIM-like, and SIM-like have been sporadically reported in some parts of the world [82], including Mediterranean countries, especially in Greece and Italy [81–85]. Concerning NDM producers, *A. baumannii* bacteria harboring these enzymes were increasingly observed around the world [86] notably in Mediterranean countries. They were detected in North Africa: Algeria [87, 88] and Libya (isolated from a patient transferred from Libya to Denmark) [89]; in Europa: France [87, 90, 91] and Slovenia [86]; and in Turkey [92]. The isolation of an NDM-1-producing *A. baumannii* in a Czech patient repatriated in 2011 from Egypt was described [93]. In France, the emergence of imported cases of NDM-1-producing *A. baumannii* was linked with Algeria [87, 90]. The strains belonged to ST85, the main clone isolated in Mediterranean countries [90, 91]. Finally, another clone NDM variant, NDM-2, was found in *A. baumannii* isolates in Egypt [94] and Israel [95].

**Figure 1:** Geographic distribution of KPC enzymes in Mediterranean countries. White, no case reported; yellow, single KPC-producing isolates; green, some outbreaks of KPC-producing isolates; orange, several outbreaks of KPC-producing isolates; red, endemicity of KPC-producing isolates.
4. Class D Carbapenemases

4.1. Enterobacteriaceae. Class D \( \beta \)-lactamases, also named OXAs for oxacillinases include 232 enzymes with few variants, possessing the same carbapenemase activity [96]. Initially OXA \( \beta \)-lactamases were reported from \( P. \) aeruginosa but until now, these carbapenemases have been detected in many other Gram-negative bacteria, including Enterobacteriaceae [16].

OXA-48 represents the main enzyme isolated around the world. This enzyme hydrolyses penicillins but has a weak activity against carbapenems or extended-spectrum cephalosporins (third generation cephalosporin, aztreonam) [2]. However, its frequent association with ESBL (notably CTX-M-15 enzyme) increases the level of resistance to carbapenem. Its activity is not inhibited by EDTA or clavulanic acid [2], tazobactam, and sulbactam, whereas its activity may be inhibited by NaCl \textit{in vitro} [96, 97]. Its high level of resistance to temocillin is interesting to detect this enzyme [98, 99]. A point mutant analog of OXA-48, namely, OXA-181, with similar carbapenemase activity, has been identified in enterobacterial strains from India [100, 101] and from patients with a link to the Indian subcontinent [100, 102]. Further analysis of the OXA-48-producing isolates demonstrated that this enzyme was not exclusively linked with a single clone, and the \( bla_{OXA-48} \) gene was associated with either transposon \( \text{Tn1999} \) or transposon \( \text{Tn1999.2} \) within transferable nontypable plasmids of 70 or 150 kb [103]. The death rates associated with OXA-producers are unknown.

OXA-48 was initially identified in \( K. \) pneumoniae isolate from Turkey in 2001 [104]. Since then, OXA-48 producing strains have been extensively reported as sources of nosocomial outbreaks in many parts of the world notably in Mediterranean countries [105–110] (Figure 3): Croatia [111], Egypt [54], France [109], Greece [112], Israel [113, 114], Italy [53], Lebanon [71, 115, 116], Libya [117], Slovenia [118], Spain [33, 119], Tunisia [120], and Turkey [106]. Moreover, this enzyme disseminated in various Enterobacteriaceae species [2, 96]. To date OXA-48 represents the most common carbapenemase type circulating in this part of the world notably in Spain [33] and France [109]. The Middle East and North Africa are considered as reservoirs of OXA-48 producers [121]. In the last few years, a nosocomial dissemination of OXA-48-producing Enterobacteriaceae has been reported in different hospitals in Morocco [122]. This problem was exacerbated by the occurrence of this enzyme in community [123] and in environment [124] suggesting that OXA-48 is endemic in this country [122]. More recently, the identification of the \( bla_{OXA-48} \) gene in a \( K. \) pneumoniae isolate has been reported in Algeria (N. Djahmi, personal data).

4.2. Acinetobacter baumannii. The class D carbapenemases (oxacillinases) are by far the most prevalent carbapenemases in \( A. \) baumannii [125, 126]. They can be grouped into six subclasses: intrinsic chromosomal OXA-51-like, among which there are over 70 variants and the acquired OXA-23-like, OXA-24/40-like, OXA-58-like, OXA-143-like, and OXA-235-like \( \beta \)-lactamases [97, 127].

The first case of OXA-type enzyme was reported from a clinical \( A. \) baumannii isolate detected in Scotland in 1985. It was initially named ARI-1 (Acinetobacter resistant to imipenem) [128] and renamed OXA-23 after sequencing.
A. radioresistens was identified as the progenitor of the \( \text{bla}_{\text{OXA-23}} \) gene [130].

Nosocomial outbreaks or sporadic cases caused by carbapenem-resistant \( A. \text{baumannii} \) producing these OXA-enzymes have been reported worldwide [80, 131–133]. \( A. \text{baumannii} \) epidemic strains were assigned to international clonal lineages I or II [134], with recent studies reporting the spread of genetically related epidemic clone of OXA-23-producing \( A. \text{baumannii} \) and belonging to IC-II within the Mediterranean region [135–137]. The \( \text{bla}_{\text{OXA-23}} \) gene was either located on the chromosome or on plasmids and was associated with four different genetic structures, with the most frequent being transposons \( \text{Tn2006} \) [134].

The emergence and spread of several outbreak or sporadic \( A. \text{baumannii} \) strains producing OXA-23-like enzymes have been reported around the world [134]. During a long period, the \( \text{bla}_{\text{OXA-58}} \) carbapenemase gene has been predominated among carbapenem-resistant \( A. \text{baumannii} \) isolates in various Mediterranean countries [85]. Since 2009, a replacement of \( \text{bla}_{\text{OXA-58}} \) gene with \( \text{bla}_{\text{OXA-23}} \) gene has been reported and it became the most prevalent carbapenemase-encoding gene circulating in the Mediterranean region: Algeria [88, 136], Croatia [III], Egypt [138], France [139], Greece [140], Italy [135, 141], Israel [132], Spain [137, 142], Tunisia [143], and Turkey [83, 144]. The replacement of OXA-58 by OXA-23 might be explained by the selective advantage associated with the higher carbapenemase activity of OXA-23 [37, 142] and/or acquisition of carbapenem resistance through horizontal gene transfer [37].

Figure 3: Geographic distribution of OXA-48 type producers in Mediterranean countries. White, no case reported; yellow, single OXA-48-producing isolates; orange, several outbreaks of OXA-48-producing isolates; red, nationwide distribution of OXA-48-producing isolates.

Concerning other OXA-producers, outbreaks of OXA-72-producing \( A. \text{baumannii} \) were described in Croatia [145] and OXA-69 or OXA-97 in Tunisia [146, 147].

5. Conclusion

In recent years the emergence of carbapenem-resistant Gram-negative bacilli in the Mediterranean region is an alarming problem. This part of the world is the cradle of western civilization representing nearly 475 million inhabitants (6.3% of world population). It is the location of a large population mixing explaining the importance of the dissemination of carbapenemase producers. This situation imposes a series of measures as soon as possible. These need the over-the-counter sale of indistinctly antibiotics, improving basic and extended knowledge on hygiene, the reinforcement of infection control measures, and the early and accurate detection, with restriction of the usage of carbapenems, to control the spread of these multidrug resistant organisms.

Conflict of Interests

The authors state that there is no conflict of interests.

References

[1] M. V. Jesudason, A. J. Kandathil, and V. Balaji, “Comparison of two methods to detect carbapenemase & metallo-\( \beta \)-lactamase production in clinical isolates,” Indian Journal of Medical Research, vol. 121, no. 6, pp. 780–783, 2005.
[2] P. Nordmann, T. Naas, and L. Poirel, “Global spread of carbapenemase producing Enterobacteriaceae,” Emerging Infectious Diseases, vol. 17, no. 10, pp. 1791–1798, 2011.

[3] Y. Carmeli, M. Akova, G. Cornaglia et al., “Controlling the spread of carbapenemase-producing Gram-negatives: therapeutic approach and infection control,” Clinical Microbiology and Infection, vol. 16, no. 2, pp. 102–111, 2010.

[4] G. Cornaglia, H. Giamarellou, and G. M. Rossolini, “Metallo-β-lactamas: a last frontier for β-lactams?” The Lancet Infectious Diseases, vol. 11, no. 5, pp. 381–393, 2011.

[5] M. Souli, I. Galani, and H. Giamarellou, “Emergence of extensively drug-resistant and pandrug-resistant Gram-negative bacilli in Europe,” Euro Surveillance, vol. 13, no. 47, 2008.

[6] H. Giamarellou and G. Poulakou, “Multidrug-resistant gram-negative infections: what are the treatment options?” Drugs, vol. 69, no. 14, pp. 1879–1901, 2009.

[7] T. Naas and P. Nordmann, “Analysis of a carbapenem-hydrolyzing class A β-lactamase from Enterobacter cloacae and of its LysR-type regulatory protein,” Proceedings of the National Academy of Sciences of the United States of America, vol. 91, no. 16, pp. 7693–7697, 1994.

[8] A. M. Queenan and K. Bush, “Carbapenemases: the versatile β-lactamases,” Clinical Microbiology Reviews, vol. 20, no. 3, pp. 440–458, 2007.

[9] T. R. Walsh, “Emerging carbapenemases: a global perspective,” International Journal of Antimicrobial Agents, vol. 36, no. 3, pp. S8–S14, 2010.

[10] F. Nahid, A. A. Khan, S. Rehman, and R. Zahra, “Prevalence of metallo-β-lactamase NDM-1-producing multi-drug resistant-bacteria at two Pakistani hospitals and implications for public health,” Journal of Infection and Public Health, vol. 6, no. 6, pp. 487–493, 2013.

[11] H. Yigit, A. M. Queenan, G. J. Anderson et al., “Novel carbapenem-hydrolyzing β-lactamase, KPC-1, from a carbapenem-resistant strain of Klebsiella pneumoniae,” Antimicrobial Agents and Chemotherapy, vol. 45, no. 4, pp. 1151–1161, 2001.

[12] P. Nordmann, G. Cuzon, and T. Naas, “The real threat of Klebsiella pneumoniae carbapenemase-producing bacteria,” The Lancet Infectious Diseases, vol. 9, no. 4, pp. 228–236, 2009.

[13] G. Cuzon, T. Naas, H. Truong et al., “Worldwide diversity of Klebsiella pneumoniae that produces β-lactamase blaKPC-2 Gene,” Emerging Infectious Diseases, vol. 16, no. 9, pp. 1349–1356, 2010.

[14] T. Naas, G. Cuzon, M.-V. Villegas, M.-E. Lartigue, J. P. Quinn, and P. Nordmann, “Genetic structures at the origin of acquisition of the β-lactamase blaKPC gene,” Antimicrobial Agents and Chemotherapy, vol. 52, no. 4, pp. 1257–1263, 2008.

[15] L. M. Deshpande, P. R. Rhomberg, H. S. Sader, and R. N. Jones, “Emergence of serine carbapenemases (KPC and SME) among clinical strains of Enterobacteriaceae isolated in the United States Medical Centers: report from the MYSTIC Program (1999–2005),” Diagnostic Microbiology and Infectious Disease, vol. 56, no. 4, pp. 367–372, 2006.

[16] Y. Pfeifer, A. Cullik, and W. Witte, “Resistance to cephalosporins and carbapenems in Gram-negative bacterial pathogens,” International Journal of Medical Microbiology, vol. 300, no. 6, pp. 371–379, 2010.

[17] A. Robustillo Rodela, C. Díaz-Agero Pérez, T. Sanchez Sagrado, P. Ruiz-Garbajosa, M. J. Pita López, and V. Monte, “Emergence and outbreak of carbapenemase-producing KPC-3 Klebsiella pneumoniae in Spain, September 2009 to February 2010: control measures,” Eurosurveillance, vol. 17, no. 7, 2012.

[18] Z. Samra, O. Ofir, Y. Lishtzinsky, L. Madar-Shapiro, and J. Bishara, “Outbreak of carbapenem-resistant Klebsiella pneumoniae producing KPC-3 in a tertiary medical centre in Israel,” International Journal of Antimicrobial Agents, vol. 30, no. 6, pp. 525–529, 2007.

[19] B. Kitchel, J. K. Rasheed, J. B. Patel et al., “Molecular epidemiology of KPC-producing Klebsiella pneumoniae isolates in the United States: clonal expansion of multilocus sequence type 258,” Antimicrobial Agents and Chemotherapy, vol. 53, no. 8, pp. 3365–3370, 2009.

[20] C. Hidalgo-Grass, G. Warburg, V. Temper et al., “KPC-9, a novel carbapenemase from clinical specimens in Israel,” Antimicrob Agents Chemother, vol. 56, pp. 6057–6059, 2012.

[21] Y. Geffen, A. Adler, S. Paikin et al., “Detection of the plasmid-mediated KPC-2 carbapenem-hydrolysing enzyme in three unusual species of the Enterobacteriaceae family in Israel,” Journal of Antimicrobial Chemotherapy, vol. 68, pp. 719–720, 2013.

[22] A. Adler, S. Paikin, Y. Sterlin et al., “A swordless knight: epidemiology and molecular characteristics of the blaKPC-negative sequence type 258 Klebsiella pneumoniae clone,” Journal of Clinical Microbiology, vol. 50, pp. 3180–3185, 2012.

[23] M. G. Goren, Y. Carmeli, M. J. Schwaber, I. Chmelnitsky, V. Schechner, and S. Navon-Venezia, “Transfer of Carbapenem-resistant plasmid from Klebsiella pneumoniae ST258 to Escherichia coli in patient,” Emerging Infectious Diseases, vol. 16, no. 6, pp. 1014–1017, 2010.

[24] J. A. Lopez, A. Correa, S. Navon-Venezia et al., “Intercontinental spread from Israel to Colombia of a KPC-3-producing Klebsiella pneumoniae strain,” Clinical Microbiology and Infection, vol. 17, no. 1, pp. 52–56, 2011.

[25] I. Chmelnitsky, O. Hermesh, S. Navon-Venezia, J. Strahilevitz, and Y. Carmeli, “Detection of aac(6’)-Ib-cr in KPC-producing Klebsiella pneumoniae isolates from Tel Aviv, Israel,” Journal of Antimicrobial Chemotherapy, vol. 64, no. 4, pp. 718–722, 2009.

[26] B. Kitchel, J. K. Rasheed, J. B. Patel et al., “Molecular epidemiology of KPC-producing Klebsiella pneumoniae isolates in the United States: clonal expansion of multilocus sequence type 258,” Antimicrobial Agents and Chemotherapy, vol. 53, no. 8, pp. 3365–3370, 2009.

[27] P. Giakkoupi, C. C. Papagiannis, V. Miriagou et al., “An update of the evolving epidemic of blaKPC-2-carrying Klebsiella pneumoniae in Greece (2009-10),” Journal of Antimicrobial Chemotherapy, vol. 66, no. 7, pp. 1510–1513, 2011.

[28] M. Souli, I. Galani, A. Antoniadou et al., “An outbreak of infection due to β-lactamase Klebsiella pneumoniae carbapenemase 2-producing K. pneumoniae in a Greek university hospital: molecular characterization, epidemiology, and outcomes,” Clinical Infectious Diseases, vol. 50, no. 3, pp. 364–373, 2010.

[29] H. Grundmann, D. M. Livermore, C. G. Giske et al., “Control of a multi-hospital outbreak of KPC-producing Klebsiella pneumoniae in a large Italian hospital: surveillance period 1 March—30 September 2010,” Eurosurveillance, vol. 16, no. 8, 2011.
type 2 in France, September to October 2009,” *Eurosurveillance*, vol. 15, no. 48, 2010.

[32] M. R. Gómez-Gil, J. R. Paño-Pardo, M. P. Romero-Gómez et al., “Detection of KPC-2-producing *Citrobacter freundii* isolates in Spain,” *Journal of Antimicrobial Chemotherapy*, vol. 65, no. 12, pp. 2695–2697, 2010.

[33] J. Oteo, D. Saez, V. Bautista et al., “Spanish collaborating group for the antibiotic resistance surveillance program. Carbapenemase-producing enterobacteriaceae in Spain in 2012,” *Antimicrobial Agents and Chemotherapy*, vol. 57, pp. 6344–6347, 2013.

[34] G. Cuzon, T. Naas, M.-C. Demachy, and P. Nordmann, “Nosocomial outbreak of *Klebsiella pneumoniae* harbouring blaKPC-3 in France subsequent to a patient transfer from Italy,” *International Journal of Antimicrobial Agents*, vol. 39, no. 5, pp. 448–449, 2012.

[35] V. Miriagou, G. Cornaglia, M. Edelstein et al., “Acquired carbapenemases in Gram-negative bacterial pathogens: detection and surveillance issues,” *Clinical Microbiology and Infection*, vol. 16, no. 2, pp. 112–122, 2010.

[36] B. Bedenić, A. Mazzariol, V. Plèčko et al., “First report of KPC-producing *Klebsiella pneumoniae* in Croatia,” *Journal of Chemotherapy*, vol. 24, no. 4, pp. 237–239, 2012.

[37] R. Zarrilli, S. Pournaras, M. Giannoulia, and A. Tsakris, “Global evolution of multidrug-resistant *Acinetobacter baumannii* clonal lineages,” *International Journal of Antimicrobial Agents*, vol. 41, no. 1, pp. 11–19, 2013.

[38] I. E. Robledo, E. E. Aquino, M. I. Santé et al., “Detection of KPC in *Acinetobacter* spp. in Puerto Rico,” *Antimicrobial Agents and Chemotherapy*, vol. 54, no. 3, pp. 1354–1357, 2010.

[39] R. A. Bonnin, P. Nordmann, A. Potron, H. Lecuyer, J.-R. Zahar, and L. Poirel, “Carbapenem-hydrolyzing GES-type extended-spectrum β-lactamase in *Acinetobacter baumannii*,” *Antimicrobial Agents and Chemotherapy*, vol. 55, no. 1, pp. 349–354, 2011.

[40] A. N. Zeka, L. Poirel, O. R. Pipali et al., “GES-type and OXA-23 carbapenemase-producing *Acinetobacter baumannii* in Turkey,” *Journal of Antimicrobial Chemotherapy*, vol. 69, no. 4, pp. 1145–1146, 2013.

[41] T. R. Walsh, M. A. Toleman, L. Poirel, and P. Nordmann, “Metallo-β-lactamases: the quiet before the storm?” *Clinical Microbiology Reviews*, vol. 18, no. 2, pp. 306–325, 2005.

[42] H. Ito, Y. Arakawa, S. Ohsuka, R. Wacharotayankun, N. Kato, and M. Ohta, “Plasmid-mediated dissemination of the metallo-β-lactamase gene bla(IMP) among clinically isolated strains of *Serratia marcescens*,” *Antimicrobial Agents and Chemotherapy*, vol. 39, no. 4, pp. 824–829, 1995.

[43] A. Vatopoulos, “High rates of metallo-β-lactamase-producing *Klebsiella pneumoniae* in Greece—a review of the current evidence,” *Euro Surveillance*, vol. 13, no. 4, 2008.

[44] P. Nordmann, L. Poirel, M. A. Toleman, and T. R. Walsh, “Does broad-spectrum β-lactamase resistance due to NDM-1 herald the end of the antibiotic era for treatment of infections caused by Gram-negative bacteria?” *Journal of Antimicrobial Chemotherapy*, vol. 66, no. 4, pp. 689–692, 2011.

[45] G. L. Daikos, P. Petrikos, M. Psychogiou et al., “Prospective observational study of the impact of VIM-1 metallo-β-lactamase on the outcome of patients with *Klebsiella pneumoniae* bloodstream infections,” *Antimicrobial Agents and Chemotherapy*, vol. 53, no. 5, pp. 1868–1873, 2009.

[46] F. Luzzaro, J.-D. Docquier, C. Colinon et al., “Emergence in *Klebsiella pneumoniae* and *Enterobacter cloacae* clinical isolates of the VIM-4 metallo-β-lactamase encoded by a conjugative plasmid,” *Antimicrobial Agents and Chemotherapy*, vol. 48, no. 2, pp. 648–650, 2004.

[47] R. Aschbacher, M. Doumith, D. M. Livermore, C. Larcher, and N. Woodford, “Linkage of acquired quinolone resistance (qnrS1) and metallo-β-lactamase (blaVIM-1) genes in multiple species of *Enterobacteriaceae* from Bolzano, Italy,” *Journal of Antimicrobial Chemotherapy*, vol. 61, no. 3, pp. 515–523, 2008.

[48] R. Aschbacher, L. Pagani, M. Doumith et al., “Metallo-β-lactamases among *Enterobacteriaceae* from routine samples in an Italian tertiary-care hospital and long-term care facilities during 2008,” *Clinical Microbiology and Infection*, vol. 17, no. 2, pp. 181–189, 2011.

[49] R. Cantón, M. Akóva, Y. Carmeli et al., “Rapid evolution and spread of carbapenemases among *Enterobacteriaceae* in Europe,” *Clinical Microbiology and Infection*, vol. 18, no. 5, pp. 413–431, 2012.

[50] L. Poirel, A. Ros, A. Carricajo et al., “Extremely drug-resistant *Citrobacter freundii* isolate producing NDM-1 and other carbapenemases identified in a patient returning from India,” *Antimicrobial Agents and Chemotherapy*, vol. 55, no. 1, pp. 447–448, 2011.

[51] M.-F. Lartigue, L. Poirel, and P. Nordmann, “First detection of a carbapenem-hydrolyzing metalloenzyme in an *Enterobacteriaceae* isolate in France,” *Antimicrobial Agents and Chemotherapy*, vol. 48, no. 12, pp. 4929–4930, 2004.

[52] A. Barguiguia, F. El Otmany, F. L. El Yaagoubi, M. Talmí, K. Zerouali, and M. Timinouni, “First report of a *Klebsiella pneumoniae* strain coproducing NDM-1, VIM-1 and OXA-48 carbapenemases isolated in Morocco,” *APMIS*, vol. 121, pp. 675–677, 2013.

[53] T. Giani, A. Marchese, E. Coppo, V. Kroumova, and G. M. Rossolini, “VIM-1-producing *Pseudomonas mossellii* isolates in Italy, predating known VIM-producing index strains,” *Antimicrobial Agents and Chemotherapy*, vol. 56, no. 4, pp. 2216–2217, 2012.

[54] L. Poirel, M. O. Abdelaziz, S. Bernabeu, and P. Nordmann, “Occurrence of OXA-48 and VIM-1 carbapenemase-producing *Enterobacteriaceae* in Egypt,” *International Journal of Antimicrobial Agents*, vol. 41, pp. 90–91, 2013.

[55] F. Robin, N. Aggounne-Khinache, J. Delmas, M. Naim, and R. Bonnet, “Novel VIM metallo-β-lactamase variant from clinical isolates of *Enterobacteriaceae* from Algeria,” *Antimicrobial Agents and Chemotherapy*, vol. 54, no. 1, pp. 466–470, 2010.

[56] S. Ktari, G. Arlet, B. Mnif et al., “Emergence of multidrug-resistant *Klebsiella pneumoniae* isolates producing VIM-4 metallo-β-lactamase, CTX-M-15 extended-spectrum β-lactamase, and CMY-4 AmpC β-lactamase in a Tunisian University Hospital,” *Antimicrobial Agents and Chemotherapy*, vol. 50, no. 12, pp. 4198–4201, 2006.

[57] F. Pasteran, E. Albornoz, D. Faccone et al., “Emergence of NDM-1-producing *Klebsiella pneumoniae* in Guatemala,” *Antimicrobial Agents and Chemotherapy*, vol. 67, no. 7, pp. 1795–1797, 2012.

[58] J. A. E. Pérez, N. M. O. Escobar, B. Castro-Cardozo et al., “Outbreak of NDM-1-producing *Klebsiella pneumoniae* in a neonatal unit in Colombia,” *Antimicrobial Agents and Chemotherapy*, vol. 57, no. 4, pp. 1957–1960, 2013.

[59] D. Yong, M. A. Toleman, C. G. Giske et al., “Characterization of a new metallo-β-lactamase gene, *bla* NDM-1, and a novel
A. Muir and M. J. Weinbren, “New Delhi metallo-β-lactamase: a cautionary tale,” Journal of Hospital Infection, vol. 75, no. 3, pp. 239–240, 2010.

P. Nordmann, L. Poirel, T. R. Walsh, and D. M. Livermore, “The emerging NDM carbapenemases,” Trends in Microbiology, vol. 19, no. 12, pp. 588–595, 2011.

M.-H. Nicolas-Chanoine, J. Blanco, V. Leflon-Guibout et al., “Intercontinental emergence of Escherichia coli clone O25:H4-ST131 producing CTX-M-15,” Journal of Antimicrobial Chemotherapy, vol. 61, no. 2, pp. 273–281, 2008.

G. Peirano, P. C. Schreckenberger, and J. D. D. Pitout, “Characteristics of NDM-1-producing Escherichia coli isolates that belong to the successful and virulent clone ST131,” Antimicrobial Agents and Chemotherapy, vol. 55, no. 6, pp. 2986–2988, 2011.

A. Birgy, C. Doit, P. Mariani-Kurkdjian et al., “Early detection of colonization by VIM-1-producing Klebsiella pneumoniae and NDM-1-producing Escherichia coli in two children returning to France,” Journal of Clinical Microbiology, vol. 49, no. 8, pp. 3085–3087, 2011.

C. Denis, L. Poirel, A. Carricajo et al., “Nosocomial transmission of NDM-1-producing Escherichia coli within a non-endemic area in France,” Clinical Microbiology and Infection, vol. 18, no. 5, pp. E128–E130, 2012.

T. Giani, B. Pini, F. Arena et al., “Epidemic diffusion of KPC carbapenemase-producing Klebsiella pneumoniae in Italy: results of the first countrywide survey,” Eurosurveillance, vol. 18, no. 22, 2013.

M. Baroud, I. Dandache, G. F. Araj et al., “Underlying mechanisms of carbapenem resistance in extended-spectrum β-lactamase-producing Klebsiella pneumoniae and Escherichia coli isolates at a tertiary care centre in Lebanon: role of OXA-48 and NDM-1 carbapenemases,” International Journal of Antimicrobial Agents, vol. 41, no. 1, pp. 75–79, 2013.

L. Poirel, A. Benouda, C. Hays, and P. Nordmann, “Emergence of NDM-1-producing Klebsiella pneumoniae in Morocco,” Journal of Antimicrobial Chemotherapy, vol. 66, no. 12, pp. 2781–2783, 2011.

M. Solé, C. Pitart, I. Roca et al., “First description of an Escherichia coli strain producing NDM-1 carbapenemase in Spain,” Antimicrobial Agents and Chemotherapy, vol. 55, no. 9, pp. 4402–4404, 2011.
from Lebanon,” Clinical Microbiology and Infection, vol. 14, no. 9, pp. 887–888, 2008.

M. Kaase, N. Pfennigwerth, F. Szabados, and S. Gatermann, “OXA-48, OXA-23 and NDM-1 carbapenemases in Gram-negative bacteria from patients from Libya,” in Abstracts of the Twenty-Second European Congress of Clinical Microbiology and Infectious Diseases, London, UK, 2012.

M. Piiri, A. Andlovic, T. Cesar et al., “A case of OXA-48 carbapenemase-producing Klebsiella pneumoniae in a patient transferred to Slovenia from Libya, November 2011,” Euro Surveillance, vol. 16, no. 50, 2011.

J. Oteo, J. M. Hernández, M. Espasa et al., “Emergence of OXA-48-producing Klebsiella pneumoniae and the novel carbapenemases OXA-244 and OXA-245 in Spain,” Journal of Antimicrobial Chemotherapy, vol. 68, no. 2, pp. 317–321, 2013.

S. Ktari, B. Mniif, F. Louati et al., “Spread of Klebsiella pneumoniae isolates producing OXA-48 β-lactamase in a Tunisian university hospital,” Journal of Antimicrobial Chemotherapy, vol. 66, no. 7, pp. 1644–1646, 2011.

L. Poirel, A. Potron, and P. Nordmann, “OXA-48-like carbapenemase: the phantom menace,” Journal of Antimicrobial Chemotherapy, vol. 67, no. 7, pp. 1597–1606, 2012.

C. Hays, A. Benouda, L. Poirel, M. Elouennass, and P. Nordmann, “Nosocomial occurrence of OXA-48-producing enterobacterial isolates in a Moroccan hospital,” International Journal of Antimicrobial Agents, vol. 39, no. 6, pp. 545–547, 2012.

A. Barguiuga, E. El Otmani, M. Talmi, K. Zerouali, and M. Timouni, “Emergence of carbapenem-resistant Enterobacteriaceae isolates in the Moroccan community,” Diagnostic Microbiology & Infectious Disease, vol. 73, no. 3, pp. 290–291, 2012.

A. Potron, L. Poirel, F. Bussy, and P. Nordmann, “Occurrence of the carbapenem-hydrolyzing β-lactamase gene blaOXA-48 in the environment in Morocco,” Antimicrobial Agents and Chemotherapy, vol. 55, no. 11, pp. 5413–5414, 2011.

L. S. Munoz-Price and R. A. Weinstein, “Acinetobacter infection,” The New England Journal of Medicine, vol. 358, no. 12, pp. 1214–1280, 2008.

J. Walther-Rasmussen and N. Høiby, “OXA-type carbapenemases,” Journal of Antimicrobial Chemotherapy, vol. 57, no. 3, pp. 373–383, 2006.

P. G. Higgins, F. J. Perez-Llarena, E. Zander, A. Fernández, G. Bou, and H. Seifert, “OXA-235, a novel class D beta-lactamase involved in resistance to carbapenems in Acinetobacter baumannii,” Antimicrobial Agents and Chemotherapy, vol. 57, pp. 2121–2126, 2013.

R. Paton, R. S. Miles, J. Hood, and S. G. B. Amyes, “ARI 1: β-lactamase-mediated imipenem resistance in Acinetobacter baumannii,” International Journal of Antimicrobial Agents, vol. 2, no. 2, pp. 81–88, 1993.

H. M. Donald, W. Scaife, S. G. B. Amyes, and H.-K. Young, “Sequence analysis of ARI-1, a novel OXA β-lactamase, responsible for imipenem resistance in Acinetobacter baumannii 6B92,” Antimicrobial Agents and Chemotherapy, vol. 44, no. 1, pp. 196–199, 2000.

L. Poirel, S. Figueiredo, V. Cattoir, A. Carattoli, and P. Nordmann, “Acinetobacter radioresistens as a silent source of carbapenem resistance for Acinetobacter spp,” Antimicrobial Agents and Chemotherapy, vol. 52, no. 4, pp. 1252–1256, 2008.

J. K. Valenzuela, L. Thomas, S. R. Partridge, T. Van Der Reijden, L. Dijkshaan, and J. Iredell, “Horizontal gene transfer in a polyclonal outbreak of carbapenem-resistant Acinetobacter baumannii,” Journal of Clinical Microbiology, vol. 45, no. 2, pp. 453–460, 2007.

P. G. Higgins, C. Dammhayn, M. Hackel, and H. Seifert, “Global spread of carbapenem-resistant Acinetobacter baumannii,” The Journal of Antimicrobial Chemotherapy, vol. 65, no. 2, pp. 233–238, 2010.

T. R. Walsh, “Emerging carbapenemases: a global perspective,” International Journal of Antimicrobial Agents, vol. 36, no. 3, pp. S8–S14, 2010.

P. D. Mugnier, L. Poirel, T. Naas, and P. Nordmann, “Worldwide dissemination of the blaOXA-23 Carbapenemase gene of Acinetobacter baumannii,” Emerging Infectious Diseases, vol. 16, no. 1, pp. 35–40, 2010.

S. D’Arezzo, L. Principe, A. Capone, N. Petrosillo, A. Petrucca, and P. Visca, “Changing carbapenemase gene pattern in an epidemic multidrug-resistant Acinetobacter baumannii lineage causing multiple outbreaks in central Italy,” Journal of Antimicrobial Chemotherapy, vol. 66, no. 1, pp. 54–61, 2011.

M. Touati, S. M. Diene, A. Racherache, M. Dekhil, A. Djahoudi, and J. M. Rolain, “Emergence of blaOXA-23 and blaOXA-54 carbapenemase-encoding genes in multidrug-resistant Acinetobacter baumannii isolates from University Hospital of Annaba, Algeria,” International Journal of Antimicrobial Agents, vol. 40, no. 1, pp. 89–91, 2012.

N. Mosqueda, P. Espinal, C. Cosgaya et al., “Globally expanding carbapenemase finally appears in Spain: nosocomial outbreak of Acinetobacter baumannii producing plasmid-encoded OXA-23 in Barcelona, Spain,” Antimicrobial Agents and Chemotherapy, vol. 57, no. 10, pp. 5155–5157, 2013.

M. Vranic-Ladavac, B. Bedenic, F. Minandri et al., “Carbapenem resistance and acquired class D β-lactamases in Acinetobacter baumannii from Croatia 2009–2010,” European Journal of Clinical Microbiology & Infectious Diseases, vol. 33, no. 3, pp. 471–478, 2014.

M. Fouad, A. S. Attia, W. M. Tawakkol, and A. M. Hashem, “Emergence of carbapenem-resistant Acinetobacter baumannii harboring the OXA-23 carbapenemase in intensive care units of Egyptian hospitals,” International Journal of Infectious Diseases, vol. 17, pp. 1252–1254, 2013.

C. Bourigaud, S. Corvec, C. Bretonnière et al., “Investigation and management of multidrug-resistant Acinetobacter baumanii spread in a French medical intensive care unit: one outbreak may hide another,” American Journal of Infection Control, vol. 41, pp. 652–653, 2013.

A. Liakopoulos, V. Miraigou, E. A. Katsifas et al., “Identification of OXA-23-producing Acinetobacter baumannii in Greece, 2010 to 2011,” Eurosurveillance, vol. 17, no. 11, 2012.

C. Mammina, D. M. Palma, C. Bonura et al., “Epidemiology and clonality of carbapenem-resistant Acinetobacter baumannii from an intensive care unit in Palermo, Italy,” BMC Research Notes, vol. 5, p. 365, 2012.

P. Espinal, M. D. Maciá, I. Roca et al., “First report of an OXA-23 carbapenemase-producing Acinetobacter baumannii clinical isolate related to Tn2006 in Spain,” Antimicrobial Agents and Chemotherapy, vol. 57, no. 1, pp. 589–591, 2013.

W. Mansour, L. Poirel, D. Betteaib, O. Bouallegue, N. Boujaifar, and P. Nordmann, “Dissemination of OXA-23-producing and carbapenem-resistant Acinetobacter baumannii in a university hospital in Tunisia,” Microbial Drug Resistance, vol. 14, no. 4, pp. 289–292, 2008.
[145] I. H. Ciftci, G. Asik, E. Karakece et al., “Distribution of blaOXA genes in Acinetobacter baumannii strains: a multicenter study,” Mikrobiyoloji Bulletin, vol. 47, pp. 592–602, 2013.

[146] I. Goic-Barisic, K. J. Towner, A. Kovacic et al., “Outbreak in Croatia caused by a new carbapenem-resistant clone of Acinetobacter baumannii producing OXA-72 carbapenemase,” Journal of Hospital Infection, vol. 77, no. 4, pp. 368–369, 2011.

[147] W. Mansour, O. Bouallegue, S. Dahmen, and N. Boujaafar, “Characterization of the resistance mechanism to β-lactams in Acinetobacter baumannii strains isolated in the university hospital Sahloul in Tunisia (2005),” Pathologie Biologie, vol. 56, no. 3, pp. 116–120, 2008.